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Background. This study assessed the non-inferiority and safety of regadenoson adminis-
tration during recovery from inadequate exercise compared with administration without
exercise.
Methods. Patients unable to achieve adequate exercise stress were randomized to rega-
denoson 0.4 mg either during recovery (Ex-Reg) or 1 hour after inadequate exercise
(Regadenoson) (MPI1). All patients also underwent non-exercise regadenoson MPI 1-14 days
later (MPI2). The number of segments with reversible perfusion defects (RPDs) detected using
single photon emission computerized tomography imaging was categorized. The primary
analysis evaluated the majority agreement rate between Ex-Reg and Regadenoson groups.
Results. 1,147 patients were randomized. The lower bound of the 95% confidence interval
of the difference in agreement rates (26%) was above the 27.5% non-inferiority margin,
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demonstrating non-inferiority of Ex-Reg to Regadenoson. Adverse events were numerically less
with Ex-Reg (MPI1). In the Ex-Reg group, one patient developed an acute coronary syndrome
and another had a myocardial infarction following regadenoson after exercise. Upon review,
both had electrocardiographic changes consistent with ischemia prior to regadenoson.
Conclusions. Administering regadenoson during recovery from inadequate exercise results
in comparable categorization of segments with RPDs and with careful monitoring appears to be
well tolerated in patients without signs/symptoms of ischemia during exercise and recovery.
(J Nucl Cardiol 2017;24:788–802.)
Key Words: Exercise Æ pharmacologic stress Æ vasodilator stress Æ myocardial perfusion
imaging Æ regadenoson
Abbreviations
ACS Acute coronary syndrome
CAD Coronary artery disease
CI Confidence interval
ECG Electrocardiogram
METs Metabolic equivalents
MI Myocardial infarction
MPHR Maximum predicted heart rate
MPI(s) Myocardial perfusion imaging(s)
RPD(s) Reversible perfusion defect(s)
SPECT Single photon emission computerized
tomography
INTRODUCTION
Exercise or pharmacological stress myocardial per-
fusion imaging (MPI) is an integral part of the non-
invasive evaluation of patients with suspected or known
coronary artery disease (CAD). Patients who are ambu-
latory and able to walk on a treadmill are often referred
for exercise MPI. However, the diagnostic accuracy of
exercise MPI studies is suboptimal in patients unable to
achieve 85% of maximum predicted heart rate (MPHR)
and 5 metabolic equivalents (METs).1 Ambulatory
patients who are not expected to achieve adequate stress
are often referred for pharmacologic stress testing
combined with low-level or symptom-limited exer-
cise.2-14 This approach has been shown to be well
tolerated, improve image quality, and diminish side
effects.5,11-14 Moreover, the addition of symptom-limited
exercise has also been shown to generate incremental
prognostic data complementary to MPI results.2 How-
ever, it is sometimes difficult to predict whether a patient
will achieve adequate exercise stress. When exercise is
inadequate, changing to pharmacological stress with
agents such as adenosine or dipyridamole can involve
delays associated with preparation for infusion. In turn,
that can disrupt lab scheduling and potentially require
rescheduling of the test to another day.1 The availability
of the pharmacologic stress agent regadenoson, which is
administered as a fixed-dose rapid injection, creates the
opportunity for its use as an adjunctive stress agent in
patients who undergo exercise testing and fail to achieve
adequate exercise stress.7-9,13,15-18 Single center studies
using regadenoson in combination with exercise have
been generally favorable;3,6-9,12,13 however, adverse
reactions have been reported.13,15 Nevertheless, the
comparability of this approach with the administration
of regadenoson without exercise has not previously been
investigated in a large clinical trial.
In order to investigate the assessment of reversible
perfusion defects (RPDs) and the safety when regade-
noson is administered during recovery following
inadequate exercise stress, we conducted the multicen-
ter, multicountry, open-label, randomized parallel
design clinical trial described herein. The objectives of
this study were to demonstrate that the strength of
agreement between single photon emission computed
tomography (SPECT) imaging with regadenoson admin-
istered during recovery following inadequate exercise
stress testing and regadenoson SPECT imaging without
exercise was not inferior to the strength of agreement
between two sequential regadenoson SPECT images
without exercise and to assess safety.
METHODS
Participants
The EXERRT study was conducted between June 29,
2012 and December 14, 2014 in the United States (44 centers),
Argentina (4 centers), and Peru (1 center). In order to be
enrolled in this phase 3b study (ClinicalTrials.gov identifier,
NCT01618669), patients must have been referred for a
clinically indicated exercise or pharmacologic stress SPECT
MPI for the evaluation of CAD. Based on the opinion of the
investigator, patients were to have a reasonable potential of
attempting exercise stress. Patients were excluded if they had
high-risk unstable angina, acute myocardial infarction (MI)
within 30 days, coronary revascularization within 1 month, a
history of second- or third-degree atrioventricular (AV) block
or left bundle branch block, pacemaker, or implantable car-
dioverter defibrillator. MET levels were estimated and not
measured directly. Caffeine-containing foods and beverages
See related editorial, pp. 803–808
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were withheld for 12 hours prior to the administration of
regadenoson. Each site followed their local protocol regarding
beta blockers. Full inclusion and exclusion criteria are listed in
the Electronic Supplementary Material.
The study was conducted in compliance with the princi-
ples of the Declaration of Helsinki, International Conference on
Harmonization of Technical Requirements for Registration of
Pharmaceuticals for Human Use, and Good Clinical Practice.
The institutional review board or independent ethics committee
of each study center approved the protocol and consent form.
Each participant provided written informed consent.
Study Design
Stress Testing and Imaging. Following a base-
line visit, patients underwent resting SPECT MPI in
accordance with American Society of Nuclear Cardiology
2009 guidelines (Fig. 1).1 For 1-day studies, sites were
instructed to use 4-12 mCi for the rest scan and 13-36 mCi
for the stress scan; for 2-day studies, sites were instructed to use
13-36 mCi for the rest scan and 13-36 mCi for the stress scan.
Patients then initiated exercise using a standard or modified
Bruce protocol.19,20 If the patient achieved C85% of MPHR
and C5 METs of activity, the patient was discontinued from the
study. If the patient did not achieve C85% of MPHR or
C5 METs of activity or both, and did not meet other
discontinuation criteria, they transitioned into a 3- to 5-minute
walking recovery. During the first 3 minutes of recovery,
patients were randomized 1:1 to either regadenoson following
exercise (Ex-Reg group) or regadenoson (Regadenoson group).
As shown in Fig. 1, Ex-Reg patients received regadenoson at
3 minutes of the walking recovery while Regadenoson patients
received regadenoson at rest 1 hour later (to allow hemody-
namics to return to baseline). SPECT imaging was performed
60-90 minutes after regadenoson administration in each group.
All patients returned 1-14 days later to undergo a second
regadenoson stress study without exercise. The first regadeno-
son scan and the baseline resting scan comprised MPI1 and the
second regadenoson scan 1-14 days later and the same baseline
resting scan comprised MPI2. Details of image processing and
analysis are included in the Electronic Supplementary Material.
Images were processed at an independent core laboratory
(ICON, Doylestown, PA), where they were interpreted by three
expert nuclear cardiology readers who were blinded to
randomization protocol, test performance, and medical history.
Images were scored using a 17-segment model with a 5-point
perfusion scale ranging from 0 = normal perfusion to 4 = ab-
sent uptake.21 Segments were counted as having a reversible
defect if the stress score was greater than the rest score and the
Radiotracer administration 
SPECT (60–90 min after radiotracer) 
Exercise (Bruce or Modified Bruce) 
Screen fail: Patients able to reach ≥85%
MPHR and ≥5 METS or meeting other
discontinuation criteria* 
Patients unable to reach ≥85%
MPHR and/or ≥5 METS
Rest MPI 
Regadenoson
administration† 
  
3 min
30 sec Radiotracer
administration 
Stress MPI1 
Ex-Reg Regadenoson
Regadenoson
administration† 
 
Radiotracer
administration 
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recovery
1.7    1.2 mph
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Radiotracer administration 
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Regadenoson administration†  
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SPECT
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Figure 1. Illustration of the flow of patients through all stages of the study. *As described in the
Methods section, patients experiencing signs or symptoms of ischemia prior to receiving
regadenoson were not to be randomized. Administered intravenously over 10 seconds. MPI,
Myocardial perfusion imaging; SPECT, single photon emission computed tomography.
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stress score was C2 (2 = moderately reduced radiotracer
uptake). Two or more segments were required to meet the
criteria for ischemia. This definition of reversible defect was
prospectively defined in the protocol and statistical plan before
any patient images were viewed by the blinded readers. Planar
imaging in the anterior view was performed immediately
following each stress SPECT scan to assess the target-to-
background ratio of heart-to-liver, heart-to-gut, and heart-to-
(the mean of) liver and gut.12,22 Data on radiation exposure
were collected.
Patients underwent 12-lead Holter monitoring during
testing, analyzed by a core laboratory for arrhythmia and 12-
lead electrocardiogram (ECG) interpretation (ERT, Philadel-
phia, PA). Patients were also monitored during the imaging
procedures for heart rate, blood pressure, and adverse events.
Criteria for Trial Discontinuation. Criteria for
discontinuation from the trial during exercise testing were
modified during the study. Initially, if a patient met an absolute
or relative indication to terminate exercise testing based on the
American College of Cardiology/American Heart Association
2002 guidelines, the investigator was to make a clinical
judgment whether to continue the patient in the trial (i.e.,
proceed with randomization).20 Following a report of an acute
coronary syndrome (ACS), the protocol was amended to
require discontinuation in patients experiencing signs or
symptoms of ischemia during exercise or recovery prior to
regadenoson administration. Full criteria for termination from
the study are listed in the Electronic Supplementary Material.
Endpoints. The primary endpoint used the number of
segments with RPDs (referred to as ischemia for this trial)
categorized as absent (0-1 segment) or present (C2 segments)
as assessed by each of the three readers. Each reader was
defined as having self-agreement based upon identical catego-
rization of a given patient as follows: 0-1 segment with RPDs
(absence of ischemia) for both MPI1 and MPI2; C2 segments
with RPDs (presence of ischemia) for both MPI1 and MPI2. A
given patient was then defined as having a majority agreement
of Yes if at least 2 of the 3 readers demonstrated self-
agreement. The primary endpoint was the binary outcome of
majority agreement of Yes or No for reader self-agreement.
The safety composite variablewas defined as the percentage
of patients who experienced at least one treatment-emergent
clinically significant cardiac event. The safety composite, sec-
ondary and safety endpoints, and the planned analyses are
described in the Electronic Supplementary Material.
Statistical Methodology
A sample size of 450 evaluable patients in each group
completing MPI1 and MPI2 would provide 90% power using
an alpha level of 5% to demonstrate non-inferiority at a margin
of 7.5%. In determining the non-inferiority margin, each group
was assumed to have a majority agreement rate of 86% based
on the regadenoson pivotal studies data.17 Assuming a 20%
dropout rate, approximately 1,130 patients would need to be
randomized.
The efficacy analysis set included all randomized patients
with interpretable MPI1 and MPI2 scans as determined by at
least two of three readers. The safety analysis set included all
randomized patients who received at least one dose of
regadenoson.
The agreement rate for each group was calculated as the
number of patients where the majority of readers agreed on
their individual assessment of the two stress MPI scans divided
by the total number of patients in the group. The primary
assessment of the non-inferiority hypothesis was provided by a
confidence interval (CI) on the difference in agreement rates
(Ex-Reg agreement rate minus Regadenoson agreement rate).
The CI was calculated using the Newcombe score methodol-
ogy.23 The lower confidence bound of the one-sided alpha
level of 0.025 of the difference in agreement rates was to
exceed -7.5% in order to demonstrate non-inferiority. The
primary efficacy assessment was performed for the efficacy
analysis set. Statistical methods for secondary endpoints are
provided in the Electronic Supplementary Material.
Role of the Funder
The funder of the study, Astellas Pharma Global Devel-
opment, Inc., was involved in study design, data collection,
data analysis, data interpretation, and writing of the report. The
corresponding author had full access to all data in the study
and all authors had final responsibility for the decision to
submit for publication.
RESULTS
Patients
Of the 1,147 patients randomized, the efficacy
analysis set included 538 patients in the Ex-Reg group
and 535 patients in the Regadenoson group (Fig. 2).
Demographics, cardiac history, and test referral were
comparable between the Ex-Reg and Regadenoson
groups (Table 1). The Bruce protocol was used in 83%
and the modified Bruce protocol in the remainder.
Patients achieved 5.4 ± 2.3 METs and a mean heart rate
that was 63.6% ± 4.6% of the MPHR. Rest and stress
testing was performed on the same day in 96% of
patients.
Primary Efficacy Endpoint
In the primary analysis, majority agreement rates
(95% CI) for the Ex-Reg and Regadenoson groups were
92% (89%, 94%) and 95% (93%, 97%), respectively.
The difference in the majority agreement rates (Ex-
Reg—Regadenoson) was -3% (95% CI: -6%, -0%).
The lower bound (-6%) was above the non-inferiority
margin of -7.5%, demonstrating that the agreement rate
for the Ex-Reg group was not inferior to the agreement
rate for the Regadenoson group (Table 2; Fig. 3). Thus,
for reader self-agreement of assessment of RPDs, Ex-
Journal of Nuclear Cardiology Thomas et al. 791
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Reg (regadenoson administered 3 minutes post exercise
during recovery at MPI1) was not inferior to Regade-
noson (regadenoson administered at rest for MPI1).
Secondary Efficacy Endpoints
The agreement rate analysis using the median
assessment of number of segments with RPDs across
the three readers categorized using two categories (0-1,
C2) did not demonstrate non-inferiority. Using three
categories (0-1, 2-4, C5), non-inferiority could not be
assessed because of insufficient data (i.e., there were no
Regadenoson group patients with C5 RPDs at MPI1)
(Table 3). Based on the median assessment, C91% of
patients had 0-1 segment with RPDs. Reader interpre-
tation was similar between the Ex-Reg and Regadenoson
groups in the evaluation of Summed Stress Scores (SSS)
categorized as 0-3, 4-7, 8-11, and C12 and Summed
Difference Scores (SDS) using the pre-defined broad
categories of 0-6, 7-13, and C14 (Electronic Supple-
mentary Material Table 1) and categorized post hoc as
0-2, 3-6, 7-13, and C14 as shown in Table 4.
Side-by-side reader assessment of the number of
RPDs comparing MPI1 to MPI2 in the Ex-Reg group
(n = 538) showed fewer RPDs in 10.6%, the same in
82.0%, and more in 7.4% of patients (P = 0.104). In the
Regadenoson group (n = 535), fewer RPDs were
observed in 9.2%, 85.8% were the same, and more in
5.0% of patients (P = 0.015).
Target-to-background ratios were higher for stress
MPI1 in the Ex-Reg group compared to the arm when
regadenoson was given at rest (Table 5). Stress MPI
image quality was similar between the groups, assessed
as excellent/good in C92% of patients in both groups
with uninterpretable scans in 1.5% of patients (Electronic
Supplementary Material Table 2). Subdiaphragmatic
activity interfering with image quality was less common
on stress MPI1 than stress MPI2 in Ex-Reg (P = 0.019)
and not different between stress MPI1 and MPI2 in
Regadenoson (P = 0.921) (Electronic Supplementary
Material Table 3).
Safety
Adverse Events. Serious adverse events occur-
ring within 24 hours of regadenoson administration
were reported for five patients (0.9%) in the Ex-Reg
group during MPI1, two patients (0.4%) in the Ex-Reg
group during MPI2, and one patient (0.2%) in each of
the MPIs for the Regadenoson group. All adverse events
occurring at a frequency C5% are reported in Table 6.
Fifty-three percent of the patients reported an adverse
event when regadenoson was administered 3 minutes
into recovery compared with 58% to 59% of patients
Screened
n = 1404
Discontinued before randomization:
Randomized
n = 1147
Ex-Reg
n = 578
Regadenoson
n = 569
Efficacy Analysis Set
n = 538
Did not receive 
regadenoson
n = 2
Did not receive 
regadenoson
n = 3
Adverse event, n = 7
Lost to follow up, n = 1
Protocol violation, n = 3
Withdrawal by patient, n = 9
Other, n = 1
Scans uninterpretable, n = 11
Adverse event, n = 16
Lost to follow up, n = 1
Protocol violation, n = 5
Withdrawal by patient, n = 9
Scans uninterpretable, n = 6
Achieved ≥ 85% MPHR and 
5 METs, n = 191
Protocol violation, n = 45
Adverse event, n = 5
Withdrawal by patient, n = 5
Other, n = 11
Total, n = 257
Safety Analysis Set
n = 575
Efficacy Analysis Set
n = 535
Safety Analysis Set
n = 567
Figure 2. Diagram outlining the flow of patients in the study, including events that precluded
patients from analysis. Reasons for exclusion from efficacy analysis set were factors that prevented
completion of all MPI assessments. MET, Metabolic equivalent; MPHR, maximum predicted heart
rate.
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when regadenoson was given without exercise. Head-
ache and flushing were numerically less in the Ex-Reg
group during MPI1. Clinically significant cardiovascular
events occurred in three patients and are discussed
below.
A 55-year-old man (Ex-Reg MPI1) was referred for
evaluation of jaw pain. He exercised for 5 minutes and
achieved 7.1 METs and 65% MPHR on the Bruce
protocol. During exercise he developed jaw pain and
downsloping inferolateral ST segment depression. Fol-
lowing administration of regadenoson, he experienced
chest pain and inferior ST elevation. Symptoms
improved after nitroglycerin. He underwent urgent
coronary angiography demonstrating two-vessel CAD
Table 1. Baseline characteristics (safety analysis set)
Parameter Ex-Reg (n 5 575) Regadenoson (n 5 567)
Age (years) 62 ± 11 62 ± 11
Male 341 (59.3) 328 (57.8)
Race
White 456 (79.3) 441 (77.8)
Black or African American 71 (12.3) 83 (14.6)
Asian 42 (7.3) 37 (6.5)
Other 6 (1.0) 6 (1.1)
BMI (kg/m2) 31 ± 7 31 ± 7
Cardiovascular history
Hypertension 504 (87.7) 489 (86.2)
Dyslipidemia 434 (75.5) 414 (73.0)
CAD 333 (57.9) 303 (53.4)
Diabetes 198 (34.4) 194 (34.2)
Previous PCI 187 (32.5) 171 (30.2)
Previous MI 145 (25.2) 122 (21.5)
Current smoker 139 (24.2) 125 (22.0)
Previous CABG 80 (13.9) 74 (13.1)
Peripheral vascular disease 64 (11.1) 53 (9.3)
Congestive heart failure 28 (4.9) 23 (4.1)
Referred for pharmacologic stress test only 274 (47.7) 257 (45.3)
Referred for exercise stress test only 270 (47.0) 270 (47.6)
Referred for pharmacologic and exercise stress tests 31 (5.4) 40 (7.1)
Exercise protocol*
Bruce protocol 448 (83.3) 442 (82.6)
Duration of exercise (min) 4.1 ± 2.3 4.1 ± 2.2
Percent of MPHR 63.2 ± 4.6 63.4 ± 4.5
Maximum METs achieved 5.9 ± 2.2 5.9 ± 2.2
Modified Bruce protocol 90 (16.7) 93 (17.4)
Duration of exercise (min) 4.7 ± 2.6 4.3 ± 2.6
Percent of MPHR 65.5 ± 4.4 64.7 ± 4.3
Maximum METs achieved 3.1 ± 1.1 2.9 ± 1.3
All patients (Combined Bruce or Modified Bruce) 538 535
Percent of MPHR 63.6 ± 4.6 63.6 ± 4.5
Maximum METs achieved 5.5 ± 2.3 5.4 ± 2.3
All values are mean ± SD or n (%)
BMI, Body mass index; CABG, coronary artery bypass grafting; CAD, coronary artery disease; MET, metabolic equivalent; MI,
myocardial infarction; MPHR, maximum predicted heart rate; PCI, percutaneous coronary intervention; SD, standard deviation;
SPECT, single photon emission computed tomography
*Percentages based on the efficacy analysis set (Ex-Reg, N = 538; Regadenoson, N = 535). Safety analysis set = patients who
received at least one dose of regadenoson during the study. Efficacy analysis set = all randomized patients who received
regadenoson study drug with interpretable SPECT scans at all visits as determined by at least two of the three blinded expert
readers
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with a subtotal right coronary artery (RCA) lesion with
thrombus. RCA aspiration thrombectomy and stenting
were successful; troponins were negative, and MI was
excluded. Aminophylline was not administered in this
patient. Criteria for discontinuation were amended
following this ACS event.
A 65-year-old man (Ex-Reg MPI1) with history of
MI, coronary artery bypass graft surgery, and diabetes
mellitus exercised for 5 minutes on the Bruce protocol
achieving 6.2 METs and 48% MPHR. During early
recovery, lateral ST depression (\1 mm) and inferior ST
elevation ([1 mm) developed. He received regadeno-
son, developing chest pain, dizziness, and dyspnea with
increasing inferior ST elevation. Symptoms resolved
and he was sent home. He presented 7.5 hours later with
an ST elevation MI. The investigator read ischemia
(4 RPDs) on SPECT imaging. Aminophylline was not
administered in this patient.
A 56-year-old man experienced chest tightness and
ST and T wave changes after stage 1 of the Bruce
protocol. Exercise was stopped and his symptoms
resolved. He was not randomized and did not receive
regadenoson. Coronary angiography revealed a subtotal
RCA occlusion that was treated with a coronary stent.
The safety composite variable, defined as the per-
centage of patients who experienced at least one
treatment-emergent clinically significant cardiac event,
is summarized in Table 6. Overall, B3% of patients in
each group experienced a significant cardiac event.
Thirteen patients in the Ex-Reg group and two patients
in the Regadenoson group showed ST depressionC2 mm
during stress MPI1 and three patients in the Ex-Reg group
and one patient in the Regadenoson group showed ST
elevation C1 mm during stress MPI1. During stress
MPI2, three patients in the Ex-Reg group and two patients
in the Regadenoson group showed ST depressionC2 mm
and two patients in Ex-Reg showed ST elevationC1 mm.
In general, the changes in ST segments were transient and
–10% –5% 0% 5%
Agreement Rate Difference
–3% –0%–6%
Boundary for Noninferiority
–7.5%
The agreement rate (SE) for Ex-Reg was 92% (1.2%)
and for Regadenoson was 95% (0.9%). The 
agreement rate difference was –3% with a lower
boundary of –6% which is greater than the 
noninferiority margin of –7.5% demonstrating
noninferiority. Thus, blinded reader self-agreement for 
the  assessment of reversible defects was not inferior
for MPI with Ex-Reg compared with Regadenoson.
Figure 3. Primary endpoint: Majority agreement rate differ-
ence (results of the primary endpoint). MPI, Myocardial
perfusion imaging; SE, standard error.
Table 2. Majority agreement between MPI1 and MPI2
Ex-Reg Regadenoson
Reader 1
(n = 524)
Reader 2
(n = 536)
Reader 3
(n = 537)
Majority
Agreement
(n = 538)
Reader 1
(n = 523)
Reader 2
(n = 528)
Reader 3
(n = 534)
Majority
Agreement
(n = 535)
Agreement
n (%)
No 47 (9.0) 68 (12.7) 44 (8.2) 44 (8.2) 36 (6.9) 48 (9.1) 33 (6.2) 26 (4.9)
Yes 477 (91.0) 468 (87.3) 493 (91.8) 494 (91.8) 487 (93.1) 480 (90.9) 501 (93.8) 509 (95.1)
Ex-Reg Regadenoson
Agreement Rate (95% CI)
92% (89% to 94%)
Agreement Rate (95% CI)
95% (93% to 97%)
Rate Difference: Group 1 ‒ Group 2 (95% CI)*
‒3% (‒6% to ‒0%)
Achieves Non- inferiority
Criteria (Yes/No)
Yes
Values are based on efficacy analysis set
CI, Confidence interval; MPI, myocardial perfusion imaging
*If the lower confidence bound of the one-sided alpha level of 0.025 of the difference in agreement rates exceeded -7.5%, non-
inferiority was demonstrated
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Table 3. Agreement rates for MPI
Agreement for 3 Categories by Number of Reversible Defects
MPI1
Median No. of 
Reversible Defects 
MPI2
Median No. of Reversible 
Defects Agreement Rate
% (95% CI)
Agreement Rate 
Difference* for All†
% (95% CI)0‒1 2‒4 ≥5 All
Ex-Reg
‒2 (‒7 to 4)
0‒1 471 27 1 499 94 (92 to 96)
2‒4 17 19 1 37 51 (34 to 68)
≥5 0 1 1 2 50 (1 to 99)
All 488 47 3 538 73 (69 to 77)
Regadenoson
0‒1 486 23 0 509 95 (93 to 97)
2‒4 11 14 1 26 54 (33 to 73)
≥5 0 0 0 0 NC
All 497 37 1 535 75 (71 to 78)
Agreement for 2 Categories by Number of Reversible Defects
MPI1
Median No. of 
Reversible Defects
MPI2
Median No. of Reversible 
Defects Agreement Rate
% (95% CI)
Agreement Rate 
Difference* for All
% (95% CI)0‒1 ≥2 All
Ex-Reg
‒1 (‒14 to 11)
0‒1 471 28 499 94 (92 to 96)
≥2 17 22 39 56 (41 to 72)
All 488 50 538 75 (68 to 83)
Regadenoson
0‒1 486 23 509 95 (94 to 97)
≥2 11 15 26 58 (39 to 77)
All 497 38 535 77 (67 to 86)
Blue highlighting added to improve clarity of overall table organization and to accentuate categories with agreement between
MPI1 and MPI2
CI, Confidence interval; MPI, myocardial perfusion imaging; NC, not calculated
*Agreement rate differences were calculated as the Ex-Reg agreement rate minus the Regadenoson agreement rate
The calculation of the ‘‘All’’ agreement rate for Ex-Reg and Regadenoson was based on the 0-1 and 2-4 categories. The C5
category was not included because of a lack of data available for the Regadenoson C5 category for MPI1. In addition, the
insufficient data for Regadenoson did not permit an agreement rate to be calculated for this row, as indicated by ‘‘NC’’
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Table 4. Summed stress scores agreement rates and summed difference scores
Agreement for Summed Stress Scores
MPI1
Mean SSS
MPI2
Mean SSS
Agreement Rate
% ± SE
Agreement Rate 
Difference* for 
Total
% (95% CI)
0‒3 4‒7 8‒11 ≥12 Total
Ex-Reg
2 (‒3 to 6)
0‒3 360 28 3 0 391 92 ± 1
4‒7 19 47 6 0 72 65 ± 6
8‒11 0 15 20 4 39 51 ± 8
≥12 0 0 2 34 36 94 ± 4
Total 379 90 31 38 538 86 ± 2
Regadenoson
0‒3 367 36 2 0 405 91 ± 1
4‒7 21 42 7 0 70 60 ± 6
8‒11 0 8 12 8 28 43 ± 9
≥12 0 0 3 29 32 91 ± 5
Total 388 86 24 37 535 84 ± 2
Summed Difference Scores
MPI2
Mean SDS
Kappa† Weighted Kappa†
MPI1
Mean SDS 0‒2 3‒6 7‒13 ≥14
Ex-Reg
0‒2 454 29 2 0
0.337 0.3743‒6 31 17 2 0
7‒13 0 0 3 0
≥14 0 0 0 0
Regadenoson
0‒2 464 34 1 0
0.348 0.4073‒6 16 13 2 0
7‒13 0 2 3 0
≥14 0 0 0 0
Blue highlighting added to improve clarity of overall table organization and to accentuate categories with agreement between
MPI1 and MPI2
CI, Confidence interval; MPI, myocardial perfusion imaging; SDS, Summed Difference Score; SE, standard error; SSS, Summed
Stress Score
*Agreement rate differences were calculated as the Ex-Reg agreement rate minus the Regadenoson agreement rate
Cohen’s Kappa and weighted Kappa statistics
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did not result in a serious cardiac event with the exception
of the 65-year-old patient discussed above. Of note, no
cases of second- or third-degree heart block or asystole
were observed in the 1,142 patients who received
regadenoson in the trial on either the site ECG or the
core laboratory Holter recording.
Heart Rate and Blood Pressure. Heart rate
increased by a mean of 10 ± 15 beats per minute (BPM)
following regadenoson administration during walk
recovery (Ex-Reg MPI1) and a mean of 21-22 BPM
when administered at rest (Fig. 4A). A decrease in mean
systolic blood pressure occurred following regadenoson
in both groups during both stress MPIs, with the largest
decrease seen in Ex-Reg MPI1 (means ranged from -4
to -17 mmHg) (Fig. 4B). Systolic blood pressures
\90 or C200 mmHg were seen in \4% of patients
(Table 7).
Radiation Dose. Approximate mean radiation
dose received for both groups was 2.8 ± 0.9 mSv during
the rest scan, 8.0 ± 1.6 mSv for each stress scan, and
18.5 ± 3.9 mSv total (total range 6.5-30.5 mSv). Actual
administered radiotracer dose was contemporaneously
recorded.
DISCUSSION
Our study addresses key issues pertinent to stress
MPI in patients who are ambulatory, but may not be able
to attain an adequate workload on treadmill exercise—a
group that constitutes a substantial proportion of patients
referred for stress MPI in current practice. The study
investigated the assessment of ischemic status and safety
of a rapid conversion of inadequate treadmill exercise to
pharmacological stress test. The primary endpoint of
non-inferiority of majority agreement rate of reader self-
agreement for the presence or absence of ischemia
between the Ex-Reg and Regadenoson groups was met.
Regadenoson administered 3 minutes post exercise
during recovery does not alter the interpretation of the
images from regadenoson administered at rest.
Target-to-background ratios were greater and sub-
diaphragmatic radiotracer interference was less frequent
when regadenoson was administered 3 minutes post
exercise during recovery than when regadenoson was
administered at rest. This was anticipated given the
increase in blood flow proportional uptake in the
myocardium, whereas exercise limits or shunts activity
from the abdominal organs. Improved counts, however,
did not translate into clear improvement in image
quality, as overall image quality was predominately
excellent/good for studies in both groups.
This protocol allows patients to attempt exercise
first, and then receive regadenoson at 3 minutes post
exercise during recovery only if adequate stress is not
achieved. This facilitates potential rapid conversion of a
non-diagnostic exercise study to a pharmacologic stress
study at the same visit. This approach allows stress
laboratories to attempt exercise first in patients who
might not need pharmacologic stress and obtain an
assessment of functional capacity.2,6 The protocol was
generally well tolerated and adverse events were con-
sistent with the known safety profile of regadenoson.
However, there were more patients with ischemic ST
segment changes (2.8%) compared to regadenoson
Table 5. Heart-to-background ratios compared within each group
Ratio Stress Stress
MPI1 MPI2 Difference (95% CI*) P value
Ex-Reg (n = 538)
Heart-to-liver 1.05 (0.40) 0.94 (0.37) 0.10 (0.10 to 0.10) \0.001
Heart-to-gut 1.12 (0.44) 0.99 (0.40) 0.15 (0.10 to 0.20) \0.001
Heart-to-liver/gut 1.02 (0.30) 0.90 (0.26) 0.10 (0.10 to 0.10) \0.001
Regadenoson (n = 535)
Heart-to-liver 0.96 (0.37) 0.95 (0.36) 0.00 (0.00 to 0.00)
Heart-to-gut 1.05 (0.43) 0.99 (0.39) 0.05 (0.00 to 0.10) NC
Heart-to-liver/gut 0.94 (0.27) 0.91 (0.26) 0.05 (0.00 to 0.10)
All values are mean ± SD
CI, Confidence interval; MPI, myocardial perfusion imaging; NC, not calculated; SD, standard deviation
*Hodges-Lehmann CI
Wilcoxon signed-rank test for Ex-Reg only
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Table 6. Treatment-emergent adverse events (safety analysis set)
TEAEs, n (%)
Ex-Reg Regadenoson
Stress MPI1
Regadenoson
Following Exercise
(n 5 575)
Stress MPI2
Regadenoson
(n 5 544)
Stress MPI1
Regadenoson
(n 5 567)
Stress MPI2
Regadenoson
(n 5 548)
Any TEAE 302 (52.5) 317 (58.3) 329 (58.0) 323 (58.9)
Drug-related TEAEs* 291 (50.6) 298 (54.8) 319 (56.3) 308 (56.2)
TEAEs leading to
discontinuation
13 (2.3) 0 5 (0.9) 1 (0.2)
Deaths 0 0 0 0
Serious TEAEs 5 (0.9) 2 (0.4) 1 (0.2) 1 (0.2)
ACS 1 (0.2) 0 0 0
Congestive heart failure 0 0 1 (0.2) 0
MI 1 (0.2) 0 0 0
Myocardial ischemia 1 (0.2) 1 (0.2) 0 0
Vision blurred 1 (0.2) 0 0 0
Pancreatitis 0 1 (0.2) 0 0
Subtherapeutic INR 0 0 0 1 (0.2)
Abnormal hepatic
enzymes
1 (0.2) 0 0 0
Dizziness 1 (0.2) 0 0 0
Speech disorder 1 (0.2) 0 0 0
Syncope 1 (0.2) 0 0 0
Most common TEAEs
Dyspnea 141 (24.5) 125 (23.0) 161 (28.4) 152 (27.7)
Headache 85 (14.8) 108 (19.9) 137 (24.2) 118 (21.5)
Dizziness 107 (18.6) 75 (13.8) 89 (15.7) 81 (14.8)
Flushing 47 (8.2) 78 (14.3) 79 (13.9) 69 (12.6)
Nausea 43 (7.5) 44 (8.1) 45 (7.9) 41 (7.5)
Chest discomfort 37 (6.4) 33 (6.1) 54 (9.5) 43 (7.8)
Abdominal pain upper 31 (5.4) 35 (6.4) 35 (6.2) 34 (6.2)
Dysgeusia 16 (2.8) 27 (5.0) 25 (4.4) 23 (4.2)
Treatment-emergent clinically significant cardiac events
Any cardiac event 17 (3.0) 5 (0.9) 3 (0.5) 2 (0.4)
Any ECG abnormality§ 16 (2.8) 5 (0.9) 3 (0.5) 2 (0.4)
ST-T depression
(C2 mm)
13 (2.3) 3 (0.6) 2 (0.4) 2 (0.4)
ST-T elevation
(C1 mm)
3 (0.5) 2 (0.4) 1 (0.2) 0
Major cardiac adverse
events
2 (0.3) 0 0 0
ACS 1 (0.2) 0 0 0
MI 1 (0.2) 0 0 0
Adverse event of
unstable angina
0 0 0 0
ACS,acutecoronarysyndrome;AV,atrioventricular;ECG,electrocardiogram; INR, internationalnormalized ratio;MI,myocardial infarction;
MPI,myocardial perfusion imaging; TEAE, treatment-emergent adverse event occurringwithin 24 hours of regadenoson administration
*Considered as possibly orprobably related to studydrugby the study investigator. Onepatient experiencedmultiple serious TEAEs.
Events occurring in C5% of patients in any group. §Other ECG abnormalities that were considered included sustained ventricular
tachycardia, ventricular fibrillation or ventricular flutter, torsade de pointes, 2:1 AV block,Mobitz I second-degreeAV block,Mobitz II
second-degree AV block, complete heart block and pause[3.0 seconds; none of these were reported for any patient
798 Thomas et al. Journal of Nuclear Cardiology
EXErcise to Regadenoson in Recovery Trial May/June 2017
administered at rest (0.4% to 0.9%; see Table 4). Also,
the protocol was associated with one patient who
developed ACS following exercise and regadenoson
and another patient who had a MI 7.5 hours following
exercise and the administration of regadenoson. Upon
case review, both of these Ex-Reg group patients
experienced ischemic symptoms and ECG changes
during exercise or recovery prior to regadenoson. In
our view, these two adverse events were avoidable. A
third patient developed significant ischemia during
submaximal exercise testing, appropriately did not
receive regadenoson, and eventually received a coronary
stent. Based on these findings, clinicians supervising an
exercise test in which regadenoson may be administered
in recovery should carefully monitor for symptoms and
ECG changes of ischemia as well as abnormal hemo-
dynamic responses to exercise during exercise and
during the 3-minute early recovery period prior to
regadenoson administration. If the supervising clinician
interprets ischemia as present during exercise or recov-
ery, then radiotracer can be administered without
regadenoson if the MPI is to proceed.
Previous studies in which low-level or symptom-
limited exercise was combined with regadenoson found
the combination to be well tolerated without serious
adverse effects and associated with improved image
quality.3,6,13 Since several prior studies have observed
that increases and decreases of asymptomatic blood
pressure can occur with the combination, the protocol
adopted for this trial allowed for a cool down prior to
regadenoson administration.3,6,13 Perhaps as a result of
this modification, we did not observe an increase in the
rate of clinically meaningful hypertension or hypoten-
sion when regadenoson was administered 3 minutes
post exercise compared to regadenoson administered at
rest.
Although previous studies of low-level exercise
with adenosine and regadenoson have often noted more
RPDs with combined exercise/vasodilator stress,2,5,10,11
in the current study the blinded readers interpreted more
RPDs on MPI2 than on MPI1 in both the Ex-Reg and
Regadenoson groups. This is consistent throughout the
assessments of their interpretations (Tables 3 and 4 and
Electronic Supplementary Material Table 1). This find-
ing is most likely related to residual radioactivity from
the resting scan generally performed on the same day as
MPI1 (‘‘shine through’’ of rest into stress). The second
stress scan (MPI2), acquired C24 hours after the resting
scan, would not have this residual activity as the resting
counts would be negligible at C24 hours.24,25 This effect
was anticipated to be small when the study was
designed, but may be larger in clinical practice than is
commonly appreciated. From a practical standpoint, this
finding raises an important clinical question whether
current widely used, same-day rest/stress, single-isotope
studies employing the guideline-recommended 1:3 dos-
ing ratio of technetium-99m agents may actually
underestimate RPDs and whether higher isotope ratios
of rest/stress (i.e., 1:4) may be needed to optimize
detection of RPDs and avoid a ‘‘shine through’’ effect.26
This aspect merits further study.
Limitations
The small number of patients with C2 segments
with RPDs limits the ability of EXERRT to investigate
changes in sensitivity for RPDs when exercise is
added to regadenoson. However, the similarity in
agreement rates (based on majority reader agreement)
on ischemic status under the two procedures does not
indicate any evidence of substantial differences in
clinical conclusions. Compared to the pivotal regade-
noson trials, fewer RPDs were seen in the current
trial.17 Nuclear imaging laboratories in the United
States currently report less ischemia than a decade or
two ago and this trend likely played a role.27,28 The
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Figure 4. Responses for heart rate (A) and systolic blood
pressure (B). Illustration of the mean and SD changes in heart
rates (A) and systolic blood pressure (B) over 60 minutes in
Ex-Reg and Regadenoson during the first and second stress
MPI procedures. MPI, Myocardial perfusion imaging; SD,
standard deviation.
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frequency of ischemia seen in our study is comparable
to that reported by contemporary nuclear laborato-
ries.27,28 In this sense, the study population was
appropriate for testing the efficacy and safety of the
Ex-Reg protocol.
Only one resting scan was obtained to which both
stress MPIs were compared. From a practical standpoint,
as there was no difference in patient clinical status
during the study period, a single scan was deemed
sufficient and enabled minimization of radiation expo-
sure for study subjects.
CONCLUSIONS
Administering regadenoson 3 minutes into recovery
following inadequate exercise provides comparable
categorization of segments with RPDs, appears to be
well tolerated, and results in improved heart-to-liver/gut
ratios. However, regadenoson should not be given
immediately after exercise to patients who develop
signs or symptoms of ischemia during exercise or
recovery.
NEW KNOWLEDGE GAINED
Patients undergoing exercise MPI who do not
achieve adequate exercise stress may be converted to a
pharmacologic test with the administration of regade-
noson at 3 minutes of recovery if a careful evaluation of
symptoms, signs, and ECG do not suggest the presence
of ischemia.
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Table 7. Hemodynamic effects (safety analysis set)
Ex-Reg Regadenoson
Hemodynamic effects*
Stress MPI1
Regadenoson
Following Exercise
(n 5 575)
Stress MPI2
Regadenoson
(n 5 544)
Stress MPI1
Regadenoson
(n 5 567)
Stress MPI2
Regadenoson
(n 5 548)
Systolic blood pressure
\90 mmHg 11 (1.9) 18 (3.3) 22 (3.9) 14 (2.6)
Decrease[35 mmHg 167 (29.2) 34 (6.3) 54 (9.5) 38 (6.9)
C200 mmHg 5 (0.9) 1 (0.2) 2 (0.4) 2 (0.4)
Increase C50 mmHg 11 (1.9) 4 (0.7) 2 (0.4) 2 (0.4)
C180 mmHg and increase of
C20 mmHg from baseline
28 (4.9) 13 (2.4) 10 (1.8) 6 (1.1)
Diastolic blood pressure
\50 mmHg 17 (3.0) 12 (2.2) 17 (3.0) 17 (3.1)
Decrease[25 mmHg 35 (6.1) 22 (4.0) 30 (5.3) 28 (5.1)
C115 mmHg 4 (0.7) 4 (0.7) 2 (0.4) 2 (0.4)
Increase C30 mmHg 13 (2.3) 10 (1.8) 6 (1.1) 6 (1.1)
Heart rate
[100 BPM 187 (43.6) 128 (23.8) 170 (30.6) 134 (24.6)
Increase[40 BPM 31 (5.4) 47 (8.6) 88 (15.5) 51 (9.3)
All values are n (%)
Baseline was defined as immediately prior to regadenoson administration. When the baseline for Ex-Reg Stress MPI1 (Re-
gadenoson Following Exercise) was defined as assessments immediately prior to exercise, the results were (n, %): systolic blood
pressure\90 mmHg (11, 1.9), decrease[35 mmHg (46, 8.0), C200 mmHg (8, 1.4), increase C50 mmHg (27, 4.7), C180 mmHg
and increase of C20 mmHg from baseline (43, 7.5); diastolic blood pressure\50 mmHg (16, 2.8), decrease[25 mmHg (35,
6.1), C115 mmHg (5, 0.9), increase C30 mmHg (17, 3.0); heart rate[100 BPM (308, 54.6), increase[40 BPM (225; 39.3)
BPM, beats per minute; MPI, myocardial perfusion imaging
*The denominator for each group is the number of patients who did not meet the criteria at baseline and had at least one non-
missing value during treatment. For each patient, the worst case among all post-baseline measurements was used
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